April 6, 2010 (FinancialWire) — OxiGene, Inc. (NASDAQ: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, appointed Tamar Howson and its current CEO, Dr. Peter J. Langecker, to its board of directors.

Howson currently serves on the boards of Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, and S*Bio Pte Ltd. She also serves as a consultant to Pitango Venture Fund and is a member of the advisory board to Triana Venture Partners. She previously served on the boards of Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept, and HBA. Howson received her M.B.A. in finance and international business from Columbia University. Educated as a chemical engineer, she holds a M.S. from the City College of New York and a B.S. from the Technion in Israel.

Peter J. Langecker, M.D., Ph.D., who joined OxiGene as Chief Development officer in June 2009 and who was named interim CEO in October 2009 and permanent CEO in February 2010, has also been appointed to OxiGene's board of directors. Dr. Langecker has over 20 years of experience in the pharmaceutical and biotechnology industry at companies such as CIBA GEIGY, Schering-Plough, Coulter Pharmaceuticals and SUGEN and he served six years on the board of directors of XCYTE Therapies in Seattle.

OxiGene is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.